This is to Inform you regarding US FDA inspection conducted today at the Company'' s CRO facility located at Taloja.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
US FDA conducted an unannounced inspection on May 8, 2026 at Alkem Laboratories' CRO facility in Taloja, Maharashtra. At the end of the inspection, no Form 483 was issued by the FDA. A Form 483 is typically issued when investigators find conditions that may violate regulations, so its absence indicates the facility passed the inspection without significant observations. The company disclosed this development to BSE and NSE as required under listing regulations.
No Form 483 issuance is a positive regulatory outcome for Alkem, suggesting the Taloja CRO facility meets compliance standards. This removes near-term regulatory risk for the company's operations and could support investor confidence in the stock.